Minnesota Legislature
Biological medical products need pharmacy law inclusion
More Minnesotans could have access to cutting-edge treatments for chronic diseases like cancer, leukemia, MS, HIV, diabetes, epilepsy and arthritis through HF712, which the House passed in a 130-0 vote Thursday.
The bill now goes to the Senate, where it is sponsored by Sen. Carla Nelson (R-Rochester).
Sponsored by Rep. Tony Albright (R-Prior Lake), the bill would update state law regarding the substitution of generic drugs to address biological products and their equivalents, called “biologics” and “biosimilars.”
“It’s a very exciting opportunity, but … we need to bring along the code as well,” Albright said on the House Floor.
Biologics are medical products made in living systems, like plant cells, and can treat the symptoms or slow the progression of many serious illnesses. But as biomedical research advances and equivalent products are created and approved by the FDA, people won’t have ready access to them under current law, Albright said.
The new legislation would update the law to allow for substitutions, as the FDA determines they are interchangeable with the prescribed biologics, unless the prescriber instructs otherwise.
Related Articles
Search Session Daily
Advanced Search OptionsPriority Dailies
Ways and Means Committee OKs proposed $512 million supplemental budget on party-line vote
By Mike Cook
Meeting more needs or fiscal irresponsibility is one way to sum up the differences among the two parties on a supplemental spending package a year after a $72 billion state budg...
Minnesota’s projected budget surplus balloons to $3.7 billion, but fiscal pressure still looms
By Rob Hubbard
Just as Minnesota has experienced a warmer winter than usual, so has the state’s budget outlook warmed over the past few months.
On Thursday, Minnesota Management and Budget...
